Post hoc analysis of 3 phase 3 placebo-controlled trials (16,979 patients): bempedoic acid lowered LDL-C similarly across ages, by 18.3% with maximal statins and 24.5% in statin-intolerant patients aged ≥75; adverse events were more frequent in those ≥75 regardless of statin.
Secondary analysisn = 16,979
Mancini et al. Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid